December 13, 2024 - 20:40

U.S. markets are showing a lack of direction as investors remain cautious ahead of next week's Federal Open Market Committee (FOMC) meeting. The Dow Jones Industrial Average, Nasdaq Composite, and S&P 500 are trading near the flatline, reflecting a wait-and-see approach among market participants.
Most analysts suggest that a 25 basis point rate cut from the Federal Reserve is already factored into current market prices. However, the uncertainty surrounding longer-term monetary policy has increased following the recent releases of Consumer Price Index (CPI) and Producer Price Index (PPI) data. This uncertainty is further compounded by the upcoming transition to a new administration in January, which has added an additional layer of complexity to the economic outlook.
As the FOMC meeting approaches, investors are keenly observing economic indicators and policy signals that could influence market trends in the coming months. The focus remains on how the Fed plans to navigate these economic challenges while balancing growth and inflation concerns.
June 3, 2026 - 07:37
Japan finance minister says ready to respond appropriately on forexTOKYO, June 3 - Japanese Finance Minister Satsuki Katayama stated on Wednesday that the government is prepared to take appropriate measures in the foreign exchange market, issuing a fresh warning...
June 2, 2026 - 17:28
Thrifts & Mortgage Finance Stocks Q1 Results: Benchmarking Franklin BSP Realty Trust (NYSE:FBRT)The close of earnings season offers a useful moment to check in on how different sectors are navigating the current economic climate. For investors keeping an eye on thrifts and mortgage finance...
June 2, 2026 - 05:00
HPE expects to achieve 2028 financial targets this year after record quarter on AI boomHewlett Packard Enterprise reported record revenue for its second fiscal quarter on Monday, driven by surging demand for AI data center infrastructure. The strong performance has led the company to...
June 1, 2026 - 02:50
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterA recent $5.5 million executive departure at Wave Life Sciences has drawn scrutiny following the company`s disappointing first-quarter performance. The clinical-stage biotech, which develops...